Last 40 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -46.07 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 4.58 | 6.04 | 3.45 | 3.17 | 4.11 | 4.80 | 4.75 | 4.59 | 15.65 | 6.88 | 7.29 | 4.53 | 6.62 | 7.33 | 10.18 | 15.21 | 7.75 | 10.01 | 9.47 | 10.66 | 14.40 |
| — | +26.0% | -27.2% | -30.9% | -73.7% | -30.3% | -34.9% | +1.2% | +136.4% | -6.1% | -28.4% | -70.2% | -14.6% | -26.8% | +7.5% | +42.6% | -46.2% | -36.9% | -36.8% | -50.8% | -15.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -14.2% | -4.0% | -2.8% | -3.7% | -3.5% | -4.6% | -4.8% | -36.4% | -23.6% | -25.3% | -25.1% | -29.7% | -27.0% | -26.2% | -25.6% | -25.6% | -17.8% | -17.6% | -13.7% | -13.3% | -11.0% |
| — | +14.0% | +41.0% | +89.8% | +85.0% | +81.7% | +80.8% | -22.5% | +12.6% | +3.6% | +1.8% | -16.0% | -52.3% | -49.4% | -86.9% | -92.3% | -61.2% | -104.4% | -48.1% | -3.9% | +0.4% | |
| ROA | -13.6% | -3.9% | -2.8% | -3.7% | -3.5% | -4.5% | -4.6% | -32.9% | -19.7% | -21.3% | -20.2% | -22.8% | -20.6% | -19.8% | -19.4% | -20.9% | -15.4% | -15.9% | -12.7% | -12.5% | -10.5% |
| — | +13.6% | +38.6% | +88.9% | +82.4% | +78.9% | +77.5% | -44.7% | +4.6% | -7.4% | -3.9% | -8.7% | -34.1% | -25.0% | -52.6% | -68.0% | -47.0% | -92.2% | -44.5% | -2.5% | +1.2% | |
| ROIC | -29.4% | -6.2% | -4.9% | -10.2% | -22.9% | -18.2% | -20.9% | -203.9% | — | — | — | — | -180.4% | -90.9% | -73.8% | -3458.9% | — | — | — | — | — |
| — | +66.0% | +76.5% | +95.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| — | -46.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 51.35 | 33.56 | 56.04 | 51.35 | 56.10 | 33.94 | 36.92 | 11.47 | 5.41 | 6.59 | 6.21 | 4.17 | 4.32 | 4.12 | 4.08 | 4.21 | 7.51 | 7.61 | 16.77 | 12.98 | 18.10 |
| — | -1.1% | +51.8% | +347.5% | +937.8% | +415.0% | +494.5% | +175.0% | +25.0% | +60.1% | +52.2% | -0.8% | -42.4% | -45.9% | -75.7% | -67.6% | -58.5% | -65.5% | -47.7% | -9.1% | -39.0% | |
| Quick Ratio | 51.35 | 33.56 | 56.04 | 51.35 | 56.10 | 33.94 | 36.92 | 11.47 | 5.41 | 6.59 | 6.21 | 4.17 | 4.32 | 4.12 | 4.08 | 4.21 | 7.51 | 7.61 | 16.77 | 12.98 | 18.10 |
| — | -1.1% | +51.8% | +347.5% | +937.8% | +415.0% | +494.5% | +175.0% | +25.0% | +60.1% | +52.2% | -0.8% | -42.4% | -45.9% | -75.7% | -67.6% | -58.5% | -65.5% | -47.7% | -9.1% | -39.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 40 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MNPR stock.
Monopar Therapeutics Inc.'s current P/E is -46.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Monopar Therapeutics Inc.'s business trajectory between earnings reports.